NMPA approval on the Sequel II CNDx system enables clinicians in China to harness PacBio HiFi sequencing for challenging conditions, with initial offering for thalassemiaMENLO PARK, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced that, through its long-standing partnership with Berry Genomics, the Sequel II CNDx system has received Class III Medical Device Registration approval from the National Medical Products ...